<DOC>
	<DOCNO>NCT01524224</DOCNO>
	<brief_summary>This study multicenter , open-label , dose-escalation phase 1 study intravenous ( IV ) LY2495655 participant advance cancer .</brief_summary>
	<brief_title>A Dose-Escalation Study Participants With Advanced Cancer</brief_title>
	<detailed_description>This study consist follow part : 1 . Dose Escalation - Cohorts least 3 participant treat increase dos LY2475655 maximum tolerate dose ( MTD ) criteria meet 1 6 dose level , 6th cohort complete without meet maximum tolerate dose criterion . 2 . Dose Confirmation - Up 10 participant enrol MTD dose level , possible define MTD dose escalation , clinical bioanalytical data review select recommend Phase 2 dose 10 additional participant enrol dose level .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Males female reproductive potential must agree use medically approve contraceptive precaution trial 3 month follow last dose study drug Females child bear potential must negative serum pregnancy test less equal 7 day prior first dose study drug Have estimate life expectancy great 12 week Have histological cytological diagnosis cancer ( exception breast prostate cancer ) advance and/or metastatic , proven effective therapy exist participant decline anticancer therapy OR Have histological cytological diagnosis metastatic breast metastatic prostate cancer receive stable antihormone therapy least 2 month Have adequate hematologic , hepatic , renal function Have performance status less equal 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , investigational therapy , least 30 day ( 6 week mitomycinC nitrosoureas ) prior study enrollment recover acute effect therapy . Participants receive antihormone therapy specify criterion exclude Have receive treatment within 30 day initial dose study drug drug receive regulatory approval indication Have serious preexist medical condition cancer ( discretion investigator ) Have central nervous system malignancy metastasis ( screen require ) Have history severe chronic disease could interfere either strength evaluation body mass assessment participation study include , limited , ischemic disease ( affect heart , brain , extremity ) , uncontrolled hypertension , uncontrolled pain , severe chronic obstructive pulmonary disease , uncompensated heart failure ( New York Heart Association Class III IV ) , uncontrolled diabetes , liver cirrhosis ( ChildPugh Class C ) Have history inherit acquire neuromuscular disease include multiple sclerosis , muscular dystrophy , myasthenia gravis Have active systemic inflammatory condition include rheumatoid arthritis , dermatomyositis , severe arthrosis , scleroderma Have unstable bone lesion , bone instability , fusion , arthroplasty , tendon repair , synovectomy , , due beforementioned condition due accident could interfere completion physical test protocol Have chronic glucocorticosteroid use great 10 mg prednisone per day equivalent Have know positive test result hepatitis B surface antigen ( HBSAg ) , hepatitis C antibody ( HCAb ) . Screening require Have untreated hypothyroidism hyperthyroidism Have history seizure , convulsion ( except previous febrile convulsion ) , stroke Present evidence major depressive disorder , history obsessive compulsive disorder , significant psychiatric disease schizophrenia , bipolar disorder , delirium Have depressive symptom associated cancer require treatment exclude drug list protocol Have previous history discontinuation monoclonal antibody therapy due allergy severe infusion reaction Are schedule start already receive anticancer hormone treatment breast prostate cancer adjuvant neoadjuvant setting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Metastases</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Advanced Cancer</keyword>
	<keyword>Metastatic Cancer</keyword>
</DOC>